Table 1.

Characteristicsof CRAB-BSI patients with Tigecycline therapy and Cefoperazone/Sulbactam therapy

	Tigecycline therapy (n = 135)	Cefoperazone/Sulbactam therapy (n = 75)	P value
Age (years)	62 (21–95)	60 (3–85)	0.086
Male sex	94 (69.6%)	55 (73.3%)	0.571
ICU admission	101 (74.8%)	55 (73.3%)	0.814
APACHE II score	20 (9–33)	18 (7–31)	0.063
APACHE II score < 20	66 (48.9%)	48 (64%)
APACHE II score ≥ 20	69 (51.1%)	27 (36%)	0.035
PBS	3 (0–7)	3 (0–8)	0.098
CPIS	7 (2–12)	6 (2–10)	0.006
28 day mortality	70 (51.9%)	22 (29.3%)	0.001
APACHE II score < 20	30.3% (20/66)	18.8%(9/48)	0.118
APACHE II score ≥ 20	72.5% (50/69)	48.1% (13/27)	0.023
Underlying disease
hypertension	58 (43.0%)	23 (30.7%)	0.053
hepatitis/cirrhosis	24 (17.8%)	19 (25.3%)	0.131
diabetes	22 (16.3%)	12 (16.0%)	0.560
renal insufficiency	23 (17.0%)	11 (14.7%)	0.406
coronary	17 (12.6%)	9 (12%)	0.544
respiratory	17 (12.6%)	8 (10.7%)	0.431
tumor	9 (6.7%)	5 (6.7%)	0.622
Comorbid conditions
pulmonary infection	51 (37.8%)	24 (32.0%)	0.247
septic shock	41 (30.4%)	5 (6.7%)	0.000
respiratory failure	24 (17.8%)	15 (20.0%)	0.412
MOF	16 (11.9%)	2 (2.7%)	0.017
abdominal cavity infection	12 (8.9%)	2 (2.7%)	0.069
stroke	3 (2.2%)	4 (5.3%)	0.208
gastrointestinal bleeding	5 (6.7%)	2 (2.7%)	0.515

Notes: Data are expressed as number (%) unless otherwise stated

Abbreviations: CRAB-BSI Acinetobacter baumannii bloodstream infection, PBS Pitt Bacteraemia Score, CPIS Clinical Pulmonary Infection Score APACHE II score, acute physiology and chronic health evaluation II, ICU intensive care unit; MOF, multiple organ failure